• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Oramed reaches 25% randomization in oral insulin trial, expects topline results in 2022

March 17, 2021 By Sean Whooley

OramedOramed Pharmaceuticals (NSDQ:ORMP) announced that it reached 25% randomization in the enrollment for its oral insulin capsule trial.

New York-based Oramed’s Phase 3 ORA-D-013-1 study for the ORMD-0801 oral insulin capsule for the treatment of Type 2 diabetes has planned for 675 patients overall, reaching a quarter of that mark in enrollment so far with a pace set to have topline results in 2022.

“We are very pleased with the pace of patient enrollment in this ORA-D-013-1 study, which keeps us on track to complete randomization of all 675 patients by the end of 2021, as we look ahead to topline results next year,” Oramed CEO Nadav Kidron said in a news release.

ORA-D-013-1 is one of two concurrent Phase 3 studies under FDA-approved protocols for treating Type 2 diabetes patients who have inadequate glycemic control over a period of six to 12 months.

The trial, which is double-blinded, placebo-controlled and multi-centered, is set to evaluate the efficacy and safety of Oramed’s oral insulin capsule, with efficacy data set to be made available after all patients complete the first six-month treatment period.

Oramed said the primary endpoint for the study is to compare the efficacy of ORMD-0801 to placebo in approving glycemic control as assessed by A1c, while the secondary endpoint is assessing the change in baseline in fasting plasma glucose at 26 weeks.

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals Tagged With: oramedpharmaceuticals

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS